Brokerages predict that Replimune Group Inc (NASDAQ:REPL) will announce earnings per share (EPS) of ($0.24) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Replimune Group’s earnings. The lowest EPS estimate is ($0.25) and the highest is ($0.23). The business is scheduled to report its next earnings report on Wednesday, February 13th.
On average, analysts expect that Replimune Group will report full-year earnings of ($1.21) per share for the current financial year, with EPS estimates ranging from ($1.34) to ($1.07). For the next year, analysts expect that the firm will report earnings of ($1.38) per share, with EPS estimates ranging from ($1.44) to ($1.31). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Replimune Group.
Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Wednesday, November 14th. The company reported ($0.26) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.06).
Institutional investors and hedge funds have recently made changes to their positions in the company. New York State Common Retirement Fund acquired a new stake in Replimune Group during the 4th quarter worth $65,000. TIAA CREF Investment Management LLC acquired a new stake in Replimune Group during the 3rd quarter worth $164,000. Bank of New York Mellon Corp raised its stake in Replimune Group by 21.2% during the 4th quarter. Bank of New York Mellon Corp now owns 24,049 shares of the company’s stock worth $240,000 after acquiring an additional 4,209 shares in the last quarter. Zimmer Partners LP acquired a new stake in Replimune Group during the 3rd quarter worth $322,000. Finally, Laurion Capital Management LP acquired a new stake in Replimune Group during the 3rd quarter worth $322,000. Institutional investors and hedge funds own 56.18% of the company’s stock.
Shares of REPL opened at $16.24 on Tuesday. Replimune Group has a twelve month low of $8.88 and a twelve month high of $23.55.
About Replimune Group
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.